Global Biobanking Market 2025-2035

Description

List of Tables

Biobanking Market Size, Share & Trends Analysis Report by Product (Equipment, Consumables, Services, And Software & Informatics) By Sample Type (Blood & Blood Products, Human Tissues, Cell Lines / Primary Cells / Pbmcs / Stem Cells, Nucleic Acids, Biological Fluids, And Microbiome) and by Application (Research & Academic Studies, Drug Discovery & Development, Diagnostics & Biomarker Development, Regenerative Medicine, Precision/Personalized Medicine And Epidemiology, Forensics, And Others) Forecast Period (2025-2035)

Industry Overview

Biobanking market was valued at $8.3 billion in 2024 and is projected to reach $20.1 billion by 2035, growing at a CAGR of 8.4% during the forecast period (2025-2035). The market drivers for biobanking include the expansion of precision and personalized medicine, necessitating extensive and diverse sample libraries for genomic research and targeted therapies. Growth in genomics and multi-omics research highlights the need for high-quality biological samples for large-scale studies. The expanding pipeline for cell and gene therapies calls for viable cell lines, particularly for complex diseases. Integrating advanced technology in biobanks enhances sample management and throughput. Increased government and private funding support the development of biobanking infrastructure. Additionally, a rising incidence of chronic diseases and an increase in clinical trials underline the demand for biospecimens for research and validation.

Market Dynamics

Advancements in Precision Medicine

The rise of precision medicine, which tailors treatment based on individual genetic profiles, has significantly increased the demand for diverse biological samples. Biobanks play a crucial role in supporting this personalized approach by providing high-quality, well-documented specimens essential for developing targeted therapies.

Expansion of Genomic Research

The growing emphasis on genomic research, driven by the need to understand genetic predispositions to diseases, has led to an increased collection and storage of DNA, RNA, and other molecular samples. Biobanks serve as repositories for these samples, facilitating large-scale studies and contributing to advancements in genetic medicine.

Technological Innovations in Biobanking

Technological advancements in cryopreservation, automation, and data management have enhanced the efficiency and scalability of biobanks. The integration of software and informatics solutions allows for better sample tracking, data analysis, and compliance with regulatory standards, thereby supporting the growth of the biobanking sector.

Market Segmentation

Based on the product, the market is segmented into equipment, consumables, services, and software & informatics.
Based on the sample type, the market is segmented into blood & blood products, human tissues, cell lines / primary cells / PBMCs / stem cells, nucleic acids, biological fluids, and microbiome.
Based on the application, the market is segmented into research & academic studies, drug discovery & development, diagnostics & biomarker development, regenerative medicine, precision/personalized medicine and epidemiology, forensics, and others.

Blood & Blood Products Largest Segment in the Global Biobanking Market

Among the various segments, blood and blood products constitute the largest share in the biobanking market. This segment's dominance is attributed to the critical role blood samples play in diagnostics, disease monitoring, and therapeutic development. The high demand for blood-derived specimens in research and clinical applications underscores their importance in the biobanking ecosystem.

Regional Outlook

The global biobanking market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Maintains Strong Market Position

In North America, the US dominates the global biobanking market, holding a major share, driven by its advanced healthcare infrastructure, extensive research and development (R&D) ecosystem, and strong government and private sector investments in precision medicine and biotechnology. The country's leadership in genomics, personalized medicine, and regenerative therapies has fueled the growth of biobanking facilities, which support large-scale sample collection, storage, and data management for clinical research and drug discovery. The presence of numerous biobanks, such as the NIH Biobank and large biorepositories maintained by academic institutions and pharmaceutical companies, strengthens the US position in the global market.

Moreover, robust funding initiatives from agencies like the National Institutes of Health (NIH) and collaborations between research organizations and biotech firms have accelerated advancements in biobank automation, data analytics, and sample traceability. The growing demand for high-quality biological samples for oncology, cardiovascular, and rare disease research further propels market expansion.

Additionally, the US benefits from favorable regulatory frameworks and technological innovations in cryopreservation, biobanking informatics, and AI-driven data management systems. With an increasing focus on population-based biobanks, such as the All of Us Research Program, and strong partnerships between healthcare providers, research institutions, and diagnostics companies, the US continues to maintain its dominant position, accounting for the largest share of the global biobanking market.

Market Players Outlook

The major companies operating in the global biobanking market include Avantor Inc., Hamilton Co., Merck KGaA, QIAGEN, Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In July 2025, India launched its first National Biobank, the Phenome India National Biobank, at the CSIR-Institute of Genomics and Integrative Biology in New Delhi. The biobank will collect genomic, clinical, and lifestyle data from 10,000 individuals across the country, aiming to transform disease diagnosis and treatment for complex conditions.
In October 2024, the National Accreditation Board for Testing and Calibration Laboratories (NABL) launched a new accreditation programme for biobanking, aligned with the international standard ISO 20387:2018. The program aims to ensure quality, traceability, and consistency in biobanking processes, crucial for medical research and drug development. The program aims to elevate operational standards across India, fostering collaboration and data sharing among research institutions, pharmaceutical companies, and healthcare providers.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global biobanking market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023989

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Biobanking Market Sales Analysis - Product | Sample Type | Application ($ Million)
Biobanking Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Biobanking Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Biobanking Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Biobanking Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Biobanking Market Revenue and Share by Manufacturers
Biobanking Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Avantor Inc.
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Hamilton Co.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Merck KGaA
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. QIAGEN
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Thermo Fisher Scientific Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Biobanking Market Sales Analysis By Product ($ Million)

5.1. Equipment
5.2. Consumables
5.3. Services
5.4. Software & Informatics

6. Global Biobanking Market Sales Analysis By Sample Type ($ Million)

6.1. Blood & Blood Products
6.2. Human Tissues
6.3. Cell lines / Primary Cells / PBMCs / Stem Cells
6.4. Nucleic Acids
6.5. Biological Fluids
6.6. Microbiome

7. Global Biobanking Market Sales Analysis By Application ($ Million)

7.1. Research & academic studies
7.2. Drug discovery & development
7.3. Diagnostics & biomarker development
7.4. Regenerative medicine
7.5. Precision/personalized medicine and epidemiology
7.6. Forensics
7.7. Others

8. Regional Analysis

8.1. North American Biobanking Market Sales Analysis - Product | Sample Type| Application($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Biobanking Market Sales Analysis - Product | Sample Type| Application($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Biobanking Market Sales Analysis - Product | Sample Type | Application ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And others)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Biobanking Market Sales Analysis - Product | Sample Type| Application($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. AutoGen
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Azenta Life Sciences
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. BD (Becton, Dickinson and Company)
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. BioLife Solutions Inc.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Charles River Laboratories
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. CryoBioSystem
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Greiner Holding AG
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Hamilton Co.
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Lonza
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. Merck KGaA
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. Promega Corp.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. QIAGEN N.V.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Revvity
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. SciSafe
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. SPT Labtech Ltd.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. STEMCELL Technologies Inc.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Tecan Trading AG
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. Thermo Fisher Scientific Inc.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. VWR International LLC
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. WiCell
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies